Odyssey Therapeutics reported a second quarter 2026 net loss of US$52.79 million, widening from US$41.24 million a year earlier, while basic and diluted loss per share from continuing operations was US$1.74 compared with US$29.54 in the prior year. For the first six months of 2026, the net loss reached US$91.05 million versus US$79.67 million in the same period of 2025, with loss per share of US$5.05 against US$67.11 a year earlier. The results and a new research and development collaboration with Evotec have refocused attention on the stock, which has returned 35.02% year to date. Odyssey Therapeutics trades at a price-to-book multiple of 2.5 times, in line with the broader US biotechs industry average but below a closer peer group average of 4.5 times.
Odyssey Therapeutics, Inc. Common StockWider net loss reported
Evotec SEEvotec collaboration mentioned but no details on impact
